Rib-X Pharmaceuticals, Inc. Watch

from S-1/A 8 pages Rib-X Pharmaceuticals, Inc. 2012 Employee Stock Purchase Plan

from S-1/A 9 pages Rib-X Pharmaceuticals, Inc. 2011 Bonus Plan

from S-1/A 6 pages Rib-X Pharmaceuticals, Inc. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant Under the Company’s 2011 Equity Incentive Plan, as Amended

from S-1/A 20 pages Rib-X Pharmaceuticals, Inc. Stock Option Grant Notice Stock Option Grant Under the Company’s 2011 Equity Incentive Plan, as Amended

from S-1/A 19 pages Rib-X Pharmaceuticals, Inc. 2011 Equity Incentive Plan, as Amended

from S-1/A 7 pages Indemnification Agreement

from S-1/A 7 pages Matthew A. Wikler, MD Chief Development Officer Rib-X Pharmaceuticals, Inc. Re: Severance Agreement Dear Dr. Wikler: You Will Be a Key Member of the Senior Management Team of Rib-X Pharmaceuticals, Inc. (The “Company”) and as a Result, the Company Will Provide You With the Following Benefits Upon Your Initial Employment With the Company. I. Definitions. for the Purposes of This Severance Agreement (This “Agreement”), Capitalized Terms Shall Have the Following Meanings: 1. “Cause” Shall Mean: (A) Your Conviction of or Your Plea of Guilty to or Confession of an Act of Fraud, Misappropriation or Embezzlement or Any Felony; or (B) Your Willful Refusal or Failure to Follow a Lawful Directive or Instruction of the Company’s Board of Directors or the Individual(s) to Whom You Report; or (C) in Carrying Out Your Duties, You Commit Material Dishonesty or You Breach a Fiduciary Duty to the Company; or (D) You Engage in Conduct Which Causes Material Injury to the Company, Monetarily or Otherwise; or (E) You Use Illegal Substances at Any Time; or (F) You Materially Breach Any Company Policies Regarding Confidentiality, Insider Trading, Any Employment Agreement With the Company Then in Effect or Your Non-Competition, Non-Disclosure and Developments Agreement. 2. “Change in Control” Shall Mean the Date: (A) Any “Person” or “Group” (As Such Terms Are Used in Section 13(d) and 14(d) of the Exchange Act) Is or Becomes the Beneficial Owner of Our Securities Representing 50% or More of the Total Voting Power of the Company’s Then-Outstanding Voting Securities, Pursuant to a Transaction Which the Company’s Board of Directors Does Not Approve; Or

from S-1/A 9 pages Employee Noncompetition, Nondisclosure and Developments Agreement

from S-1/A 4 pages April 6, 2012 Matthew A. Wikler, MD Po Box 5000, Pmb 84 Rancho Santa Fe, Ca 92067 Dear Dr. Wikler, We Are Very Pleased to Offer You Employment at Rib-X Pharmaceuticals (“Rib-X”). Your Start Date Will Be Effective on or Around April 30, 2012. We Are Very Enthusiastic About the Prospect of Your Joining the Rib-X Team, and Are Confident of a Mutually Beneficial Relationship. Position and Compensation

from S-1/A 7 pages Employee Noncompetition, Nondisclosure and Developments Agreement

from S-1/A 7 pages Employee Noncompetition, Nondisclosure and Developments Agreement

from S-1/A 6 pages Employee Noncompetition, Nondisclosure and Developments Agreement

from S-1/A 6 pages Employee Noncompetition, Nondisclosure and Developments Agreement

from S-1/A 6 pages Employee Noncompetition, Nondisclosure and Developments Agreement

from S-1/A 6 pages Employee Noncompetition, Nondisclosure and Developments Agreement

from S-1/A 6 pages Rib-X Pharmaceuticals, Inc. Employee Non-Disclosure and Developments Agreement

from S-1/A 7 pages [Name] [Title] Rib-X Pharmaceuticals, Inc. Re: Severance Agreement Dear [Name]: You Are a Key Member of the Senior Management Team of Rib-X Pharmaceuticals, Inc. (The “Company”). as a Result, the Company Is Providing You With the Following Benefits in Consideration of Your Continued Employment With the Company. I. Definitions. for the Purposes of This Severance Agreement (This “Agreement”), Capitalized Terms Shall Have the Following Meanings: 1. “Cause” Shall Mean: (A) Your Conviction of or Your Plea of Guilty to or Confession of an Act of Fraud, Misappropriation or Embezzlement or Any Felony; (B) Your Willful Refusal or Failure to Follow a Lawful Directive or Instruction of the Company’s Board of Directors or the Individual(s) to Whom You Report; (C) in Carrying Out Your Duties, You Commit Material Dishonesty or You Breach a Fiduciary Duty to the Company; (D) You Engage in Conduct Which Causes Material Injury to the Company, Monetarily or Otherwise; (E) You Use Illegal Substances at Any Time; or (F) You Materially Breach Any Company Policies Regarding Confidentiality, Insider Trading, Any Employment Agreement With the Company Then in Effect or Your Employee Noncompetition, Nondisclosure and Developments Agreement. 2. “Change in Control” Shall Mean the Date

from S-1/A 97 pages Yale Exclusive License Agreement

from S-1/A 45 pages License and Supply Agreement

from S-1/A 80 pages Collaboration and License Agreement by and Between Rib-X Pharmaceuticals, Inc. and Sanofi Effective as of June 28, 2011